Today's Peptide News — September 10, 2026

A new review in Frontiers in Medicine consolidates a fast-growing body of evidence that antimicrobial peptides (AMPs) — cationic, amphipathic molecules long prized as broad-spectrum antibiotics — are increasingly viable anticancer agents. Their positive charge lets them selectively engage the negatively charged membranes of malignant cells, driving rapid, targeted membrane disruption and cell lysis while largely sparing healthy tissue. The review catalogs roughly a dozen peptides already in clinical testing, alongside a growing pipeline of AMP-derived candidates and peptide cancer vaccines.

Why it matters: AMPs sit at the intersection of two of oncology's hardest problems — drug-resistant infections in immunocompromised patients and selective tumor killing — and their membrane-lytic mechanism is hard for cancers to evade through conventional resistance pathways.

Suggested PeptideWiki angle: A primer on "How antimicrobial peptides became anticancer drugs," explaining the electrostatic selectivity mechanism in plain terms and listing the AMPs currently in the clinic.

Researchers report proteolytically stable, amphiphilic peptide hydrogelators engineered for two therapeutic jobs at once: killing drug-resistant bacterial strains and killing triple-negative breast cancer cells. By tuning the structure-activity relationship of the cationic peptides, the team produced soft materials that resist enzymatic breakdown — a chronic weakness of peptide drugs — while retaining potent dual activity.

Why it matters: Proteolytic instability is one of the biggest reasons promising peptides fail in the body. A stable hydrogel platform that self-assembles and delivers both antibacterial and anticancer action points toward local, implantable therapies for hard-to-treat tumors and infected surgical sites.

Suggested PeptideWiki angle: A short explainer on peptide self-assembly and why "proteolytic stability" is the property that turns a lab-active peptide into a real drug.

A bioRxiv preprint introduces PeptiVerse, a unified machine-learning platform for predicting the drug-relevant properties of therapeutic peptides. It accepts either plain amino-acid sequences or chemically modified peptides encoded as SMILES strings, and reports state-of-the-art performance across a range of property-prediction tasks — the kind of screening that normally requires many separate specialized models.

Why it matters: Peptide drug discovery increasingly lives or dies on computational triage. A single model that handles both natural sequences and chemically modified peptides lowers the barrier for labs designing next-generation candidates and helps prioritize which molecules ever reach the bench.

Suggested PeptideWiki angle: A explainer on how AI is speeding up peptide design, using PeptiVerse to illustrate what "property prediction" actually means for stability, toxicity, and activity.

Novo Nordisk's amycretin — a first-in-class, unimolecular long-acting agonist that hits both the GLP-1 and amylin receptors — is moving into late-stage development after striking early results. In a randomized, placebo-controlled phase 1b/2a study of 125 adults with overweight or obesity, participants on the highest 20 mg subcutaneous dose lost an average of about 22% of body weight over 36 weeks, versus a roughly 2% gain on placebo. The molecule is being developed in both once-weekly injectable and once-daily oral forms.

Why it matters: A single peptide that combines GLP-1 and amylin action in one molecule could rival Eli Lilly's tirzepatide and retatrutide while simplifying dosing. The 22% figure in just 36 weeks is among the strongest early efficacy signals in the obesity field.

Suggested PeptideWiki angle: A profile page on amycretin — what "unimolecular dual agonist" means, how it differs from combination drugs like CagriSema, and where it stands in trials.

Novo Nordisk's CagriSema — a fixed-dose combination of the GLP-1 agonist semaglutide and the long-acting amylin analog cagrilintide — continues to build its case for approval as the first therapy of its kind. In the phase 3 REDEFINE 2 trial, participants with overweight or obesity and type 2 diabetes lost a mean of 13.7% of body weight versus 3.4% on placebo, and separate phase 3 data showed superior HbA1c reduction and weight loss versus semaglutide alone across tested doses. The combination is under FDA review and could reach the market later in 2026.

Why it matters: CagriSema would validate amylin as a commercial obesity target alongside GLP-1, opening a new mechanistic pillar for metabolic disease and giving clinicians a combination option distinct from single-molecule agonists.

Suggested PeptideWiki angle: A comparison post — CagriSema (two peptides combined) versus amycretin (one peptide, two receptors) — to teach readers the difference between combination and unimolecular approaches.

An industry analysis from PatentVest documents an "amylin renaissance": roughly 40 active programs and about $19 billion in deals as Lilly, Novo Nordisk, Roche, AstraZeneca, Pfizer, AbbVie, Structure Therapeutics and others race to build the next pillar of obesity medicine around the amylin pathway. Companies are pursuing amylin through standalone peptides, GLP-1/amylin combinations, unimolecular dual agonists, and oral small molecules.

Why it matters: After a decade dominated by GLP-1, capital and clinical attention are shifting toward amylin as the mechanism most likely to extend weight loss and diversify the field. The scale of investment signals that amylin peptides will define the next several years of metabolic drug development.

Suggested PeptideWiki angle: A landscape overview of the amylin pipeline — what amylin does physiologically, and a scannable list of the leading peptide programs and who owns them.

The FDA has authorized Aletta, developed by Dutch company Vitestro — the first standalone robotic system that can draw blood from a patient's arm without hands-on operator intervention. Cleared on August 19, 2026 through the De Novo pathway, the device matched or exceeded trained phlebotomists' successful-puncture rates across patients with difficult venous access and different skin tones. It is authorized for adults in outpatient settings under the oversight of a trained supervisor, with one phlebotomist able to monitor up to three devices at once.

Why it matters: Blood draws are among the most common medical procedures, and phlebotomist shortages are a persistent bottleneck. Autonomous, consistent venipuncture could expand access and reduce failed sticks — a notable early example of physical AI entering routine clinical care.

Researchers at Queen Mary University of London report that caffeine activates AMPK — an evolutionarily ancient energy sensor that acts like a cellular fuel gauge — rather than simply blocking the growth regulator TOR as previously thought. Working in fission yeast, the team found caffeine reaches TOR indirectly by first waking up AMPK, in turn triggering DNA repair, stress resistance, and metabolic balance, all processes tied to how cells age. The study appears in the journal Microbial Cell.

Why it matters: AMPK and TOR are conserved across hundreds of millions of years of evolution and are central targets in aging research. Clarifying that caffeine works primarily through AMPK sharpens our understanding of why coffee consumption is repeatedly linked to healthier aging — though the work is in yeast and far from a human prescription.

A large study published in CANCER, the American Cancer Society's peer-reviewed journal, links a new cancer diagnosis to a sharply elevated stroke risk. Analyzing 182,221 Israeli adults aged 40 and older diagnosed with a first invasive cancer between 2014 and 2021, researchers found roughly 80% more ischemic strokes than expected from the general population, with risk peaking in the first three months after diagnosis at about 2.5 times the baseline rate. Pancreatic and lung cancers carried the highest stroke rates, while breast and prostate cancers were not linked to elevated risk.

Why it matters: The finding suggests newly diagnosed cancer patients — especially younger patients and those with advanced disease — may benefit from closer cardiovascular monitoring in the critical first months, when treatment planning is already intense.